NCT01233947View on ClinicalTrials.gov

Study of AFP464 +/- Faslodex in ER + Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Breast Neoplasm
Interventions
DRUG

AFP464

AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle

DRUG

AFP464 + Faslodex

AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label

Trial Locations (1)

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

Sponsors
All Listed Sponsors
lead

Tigris Pharmaceuticals

INDUSTRY

NCT01233947 - Study of AFP464 +/- Faslodex in ER + Breast Cancer | Biotech Hunter | Biotech Hunter